{"transactions":[{"id":4614748,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":183097,"kind":"person","name":"van Grunsven Jasper","position":1,"cik":"0002154061","reported_name":"van Grunsven Jasper","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,   CP and NPPO"}}],"security":"Common Stock","published_at":"2026-09-10T20:31:53.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":8682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on 09/08/2027."}],"balance_after":8682,"source":{"system":"sec-edgar","filing":"0000875320-26-000272","document":"wk-form4_1789072310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2154061/000087532026000272/wk-form4_1789072310.xml","form_type":"4"}},{"id":305531,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:39:35.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 03/01/2029."}],"balance_after":11624,"source":{"system":"sec-edgar","filing":"0000875320-26-000267","document":"wk-form4_1788295172.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000267/wk-form4_1788295172.xml","form_type":"4"}},{"id":305605,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14205,"kind":"person","name":"SACHS BRUCE I","position":1,"cik":"0001197036","reported_name":"SACHS BRUCE I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T20:20:11.000Z","date":"2026-08-27","kind":"gift","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39000,"source":{"system":"sec-edgar","filing":"0000875320-26-000261","document":"wk-form4_1788207608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000261/wk-form4_1788207608.xml","form_type":"4"}},{"id":306910,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-07-23T20:15:41.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":8251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 03/31/2030."}],"balance_after":53572,"source":{"system":"sec-edgar","filing":"0000875320-26-000253","document":"wk-form4_1784837739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000253/wk-form4_1784837739.xml","form_type":"4"}},{"id":306911,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-07-23T20:13:11.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":8251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests on 03/31/2030."}],"balance_after":66512,"source":{"system":"sec-edgar","filing":"0000875320-26-000251","document":"wk-form4_1784837586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000251/wk-form4_1784837586.xml","form_type":"4"}},{"id":307087,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14205,"kind":"person","name":"SACHS BRUCE I","position":1,"cik":"0001197036","reported_name":"SACHS BRUCE I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-07-17T20:06:40.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":99.941,"price":475.28,"value":47499.95848,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."}],"balance_after":15771.807,"derivative":{"underlying":"Common Stock","underlying_shares":99.941},"source":{"system":"sec-edgar","filing":"0000875320-26-000249","document":"wk-form4_1784318797.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000249/wk-form4_1784318797.xml","form_type":"4"}},{"id":307088,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14410,"kind":"person","name":"Garber Alan M","position":1,"cik":"0001312907","reported_name":"Garber Alan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-07-17T20:05:47.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":31.56,"price":475.28,"value":14999.8368,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."}],"balance_after":65.458,"derivative":{"underlying":"Common Stock","underlying_shares":31.56},"source":{"system":"sec-edgar","filing":"0000875320-26-000247","document":"wk-form4_1784318742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000247/wk-form4_1784318742.xml","form_type":"4"}},{"id":307413,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-07-07T20:15:41.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":524.99,"value":787485.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":45321,"source":{"system":"sec-edgar","filing":"0000875320-26-000245","document":"wk-form4_1783455338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000245/wk-form4_1783455338.xml","form_type":"4"}},{"id":307414,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-07-07T20:08:03.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":1541,"price":519,"value":799779.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":11001,"source":{"system":"sec-edgar","filing":"0000875320-26-000243","document":"wk-form4_1783454880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000243/wk-form4_1783454880.xml","form_type":"4"}},{"id":307456,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14445,"kind":"person","name":"Liu Joy","position":1,"cik":"0001847529","reported_name":"Liu Joy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-06T20:13:10.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":828,"price":502.71,"value":416243.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":19131,"source":{"system":"sec-edgar","filing":"0000875320-26-000241","document":"wk-form4_1783368787.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000241/wk-form4_1783368787.xml","form_type":"4"}},{"id":307711,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-06-30T20:09:42.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":596,"price":482.5,"value":287570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":15337,"source":{"system":"sec-edgar","filing":"0000875320-26-000239","document":"wk-form4_1782850180.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000239/wk-form4_1782850180.xml","form_type":"4"}},{"id":307946,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-06-23T20:08:57.000Z","date":"2026-06-18","kind":"sale","planned":true,"acquired":false,"shares":1020,"price":462.17,"value":471413.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":15933,"source":{"system":"sec-edgar","filing":"0000875320-26-000237","document":"wk-form4_1782245334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000237/wk-form4_1782245334.xml","form_type":"4"}},{"id":308211,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-06-17T20:12:35.000Z","date":"2026-06-15","kind":"sale","planned":true,"acquired":false,"shares":4062,"price":450,"value":1827900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":16953,"source":{"system":"sec-edgar","filing":"0000875320-26-000235","document":"wk-form4_1781727153.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000235/wk-form4_1781727153.xml","form_type":"4"}},{"id":308630,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-06-09T20:24:24.000Z","date":"2026-06-05","kind":"sale","planned":true,"acquired":false,"shares":1745,"price":450,"value":785250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":21015,"source":{"system":"sec-edgar","filing":"0000875320-26-000233","document":"wk-form4_1781036661.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000233/wk-form4_1781036661.xml","form_type":"4"}},{"id":308824,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14445,"kind":"person","name":"Liu Joy","position":1,"cik":"0001847529","reported_name":"Liu Joy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-03T20:06:33.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":828,"price":439.91,"value":364245.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":19959,"source":{"system":"sec-edgar","filing":"0000875320-26-000230","document":"wk-form4_1780517191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000230/wk-form4_1780517191.xml","form_type":"4"}},{"id":308852,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-06-02T20:04:23.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":1974,"price":450,"value":888300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":22760,"source":{"system":"sec-edgar","filing":"0000875320-26-000228","document":"wk-form4_1780430661.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000228/wk-form4_1780430661.xml","form_type":"4"}},{"id":309434,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14631,"kind":"person","name":"Bunnage Mark E.","position":1,"cik":"0002100735","reported_name":"Bunnage Mark E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:02.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":33,"price":453.45,"value":14963.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025."}],"balance_after":7284,"source":{"system":"sec-edgar","filing":"0000875320-26-000226","document":"wk-form4_1779221100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000226/wk-form4_1779221100.xml","form_type":"4"}},{"id":309435,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-05-19T20:04:21.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":1354,"price":453.45,"value":613971.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":24734,"source":{"system":"sec-edgar","filing":"0000875320-26-000225","document":"wk-form4_1779221059.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000225/wk-form4_1779221059.xml","form_type":"4"}},{"id":309670,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-05-14T20:10:04.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":6988,"price":450,"value":3144600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":26088,"source":{"system":"sec-edgar","filing":"0000875320-26-000222","document":"wk-form4_1778789402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000222/wk-form4_1778789402.xml","form_type":"4"}},{"id":310062,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14716,"kind":"person","name":"Upadhyay Suketu","position":1,"cik":"0001533149","reported_name":"Upadhyay Suketu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-05-05T21:44:07.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay  deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay  is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."}],"balance_after":3595.156,"derivative":{"underlying":"Common Stock","underlying_shares":796},"source":{"system":"sec-edgar","filing":"0000875320-26-000193","document":"wk-form4_1778017445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000193/wk-form4_1778017445.xml","form_type":"4"}},{"id":310061,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14716,"kind":"person","name":"Upadhyay Suketu","position":1,"cik":"0001533149","reported_name":"Upadhyay Suketu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:44:07.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":2866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":2866,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":2866},"source":{"system":"sec-edgar","filing":"0000875320-26-000193","document":"wk-form4_1778017445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000193/wk-form4_1778017445.xml","form_type":"4"}},{"id":310060,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14716,"kind":"person","name":"Upadhyay Suketu","position":1,"cik":"0001533149","reported_name":"Upadhyay Suketu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:44:07.000Z","date":"2026-05-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2025, Mr. Upadhyay  deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay  is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."}],"balance_after":1558,"source":{"system":"sec-edgar","filing":"0000875320-26-000193","document":"wk-form4_1778017445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000193/wk-form4_1778017445.xml","form_type":"4"}},{"id":310066,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-05-05T21:37:29.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":398,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death."}],"balance_after":398,"derivative":{"underlying":"Common Stock","underlying_shares":398},"source":{"system":"sec-edgar","filing":"0000875320-26-000191","document":"wk-form4_1778017046.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000191/wk-form4_1778017046.xml","form_type":"4"}},{"id":310065,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:37:29.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":1433,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1433},"source":{"system":"sec-edgar","filing":"0000875320-26-000191","document":"wk-form4_1778017046.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000191/wk-form4_1778017046.xml","form_type":"4"}},{"id":310064,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:37:29.000Z","date":"2026-05-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units."}],"balance_after":2109,"source":{"system":"sec-edgar","filing":"0000875320-26-000191","document":"wk-form4_1778017046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000191/wk-form4_1778017046.xml","form_type":"4"}},{"id":310063,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":10183,"kind":"person","name":"Thornberry Nancy","position":1,"cik":"0001797826","reported_name":"Thornberry Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:37:29.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":2507,"source":{"system":"sec-edgar","filing":"0000875320-26-000191","document":"wk-form4_1778017046.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000191/wk-form4_1778017046.xml","form_type":"4"}},{"id":310070,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14717,"kind":"person","name":"Schneider Jennifer","position":1,"cik":"0001783060","reported_name":"Schneider Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-05-05T21:29:42.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Schneider's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Schneider's disability or death."}],"balance_after":796,"derivative":{"underlying":"Common Stock","underlying_shares":796},"source":{"system":"sec-edgar","filing":"0000875320-26-000189","document":"wk-form4_1778016579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000189/wk-form4_1778016579.xml","form_type":"4"}},{"id":310069,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14717,"kind":"person","name":"Schneider Jennifer","position":1,"cik":"0001783060","reported_name":"Schneider Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:29:42.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":1433,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1433},"source":{"system":"sec-edgar","filing":"0000875320-26-000189","document":"wk-form4_1778016579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000189/wk-form4_1778016579.xml","form_type":"4"}},{"id":310068,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14717,"kind":"person","name":"Schneider Jennifer","position":1,"cik":"0001783060","reported_name":"Schneider Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:29:42.000Z","date":"2026-05-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Dr. Schneider on May 1, 2025, Dr. Schneider deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Dr. Schneider is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."}],"balance_after":1394,"source":{"system":"sec-edgar","filing":"0000875320-26-000189","document":"wk-form4_1778016579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000189/wk-form4_1778016579.xml","form_type":"4"}},{"id":310067,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14717,"kind":"person","name":"Schneider Jennifer","position":1,"cik":"0001783060","reported_name":"Schneider Jennifer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:29:42.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":2190,"source":{"system":"sec-edgar","filing":"0000875320-26-000189","document":"wk-form4_1778016579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000189/wk-form4_1778016579.xml","form_type":"4"}},{"id":310071,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14205,"kind":"person","name":"SACHS BRUCE I","position":1,"cik":"0001197036","reported_name":"SACHS BRUCE I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:24:45.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":2866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":2866,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":2866},"source":{"system":"sec-edgar","filing":"0000875320-26-000187","document":"wk-form4_1778016282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000187/wk-form4_1778016282.xml","form_type":"4"}},{"id":310074,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14718,"kind":"person","name":"MCKENZIE DIANA","position":1,"cik":"0001754648","reported_name":"MCKENZIE DIANA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-05-05T21:18:16.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death."}],"balance_after":7787.483,"derivative":{"underlying":"Common Stock","underlying_shares":796},"source":{"system":"sec-edgar","filing":"0000875320-26-000185","document":"wk-form4_1778015893.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000185/wk-form4_1778015893.xml","form_type":"4"}},{"id":310073,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14718,"kind":"person","name":"MCKENZIE DIANA","position":1,"cik":"0001754648","reported_name":"MCKENZIE DIANA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:18:16.000Z","date":"2026-05-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":796,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units."}],"balance_after":2378,"source":{"system":"sec-edgar","filing":"0000875320-26-000185","document":"wk-form4_1778015893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000185/wk-form4_1778015893.xml","form_type":"4"}},{"id":310072,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14718,"kind":"person","name":"MCKENZIE DIANA","position":1,"cik":"0001754648","reported_name":"MCKENZIE DIANA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T21:18:16.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":3174,"source":{"system":"sec-edgar","filing":"0000875320-26-000185","document":"wk-form4_1778015893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000185/wk-form4_1778015893.xml","form_type":"4"}},{"id":310075,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14445,"kind":"person","name":"Liu Joy","position":1,"cik":"0001847529","reported_name":"Liu Joy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-05T21:11:22.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1104,"price":425.02,"value":469222.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":20729,"source":{"system":"sec-edgar","filing":"0000875320-26-000183","document":"wk-form4_1778015480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/wk-form4_1778015480.xml","form_type":"4"}},{"id":310076,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14719,"kind":"person","name":"Lagarde Michel","position":1,"cik":"0001518973","reported_name":"Lagarde Michel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T21:06:54.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":2866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":2866,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":2866},"source":{"system":"sec-edgar","filing":"0000875320-26-000181","document":"wk-form4_1778015211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000181/wk-form4_1778015211.xml","form_type":"4"}},{"id":310078,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14410,"kind":"person","name":"Garber Alan M","position":1,"cik":"0001312907","reported_name":"Garber Alan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T20:58:47.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":1433,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1433},"source":{"system":"sec-edgar","filing":"0000875320-26-000179","document":"wk-form4_1778014724.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000179/wk-form4_1778014724.xml","form_type":"4"}},{"id":310077,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14410,"kind":"person","name":"Garber Alan M","position":1,"cik":"0001312907","reported_name":"Garber Alan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T20:58:47.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":7344,"source":{"system":"sec-edgar","filing":"0000875320-26-000179","document":"wk-form4_1778014724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000179/wk-form4_1778014724.xml","form_type":"4"}},{"id":310079,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":10992,"kind":"person","name":"CARNEY LLOYD","position":1,"cik":"0001204424","reported_name":"CARNEY LLOYD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T20:54:30.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":2866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":2866,"derivative":{"exercise_price":424.45,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":2866},"source":{"system":"sec-edgar","filing":"0000875320-26-000177","document":"wk-form4_1778014467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000177/wk-form4_1778014467.xml","form_type":"4"}},{"id":310081,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14720,"kind":"person","name":"Bhatia Sangeeta N.","position":1,"cik":"0001643921","reported_name":"Bhatia Sangeeta N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T20:51:19.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":318,"price":423.73,"value":134746.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025."}],"balance_after":4924,"source":{"system":"sec-edgar","filing":"0000875320-26-000175","document":"wk-form4_1778014276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000175/wk-form4_1778014276.xml","form_type":"4"}},{"id":310080,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14720,"kind":"person","name":"Bhatia Sangeeta N.","position":1,"cik":"0001643921","reported_name":"Bhatia Sangeeta N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-05T20:51:19.000Z","date":"2026-05-01","kind":"grant","planned":true,"acquired":true,"shares":943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date."}],"balance_after":5242,"source":{"system":"sec-edgar","filing":"0000875320-26-000175","document":"wk-form4_1778014276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000175/wk-form4_1778014276.xml","form_type":"4"}},{"id":310643,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14716,"kind":"person","name":"Upadhyay Suketu","position":1,"cik":"0001533149","reported_name":"Upadhyay Suketu","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-04-17T20:20:37.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":80.508,"price":442.5,"value":35624.79,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death."}],"balance_after":2799.156,"derivative":{"underlying":"Common Stock","underlying_shares":80.508},"source":{"system":"sec-edgar","filing":"0000875320-26-000163","document":"wk-form4_1776457233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000163/wk-form4_1776457233.xml","form_type":"4"}},{"id":310644,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14205,"kind":"person","name":"SACHS BRUCE I","position":1,"cik":"0001197036","reported_name":"SACHS BRUCE I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-04-17T20:17:34.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":107.345,"price":442.5,"value":47500.1625,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death."}],"balance_after":15671.866,"derivative":{"underlying":"Common Stock","underlying_shares":107.345},"source":{"system":"sec-edgar","filing":"0000875320-26-000161","document":"wk-form4_1776457052.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000161/wk-form4_1776457052.xml","form_type":"4"}},{"id":310645,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14410,"kind":"person","name":"Garber Alan M","position":1,"cik":"0001312907","reported_name":"Garber Alan M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-04-17T20:14:55.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":33.898,"price":442.5,"value":14999.865,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."}],"balance_after":33.898,"derivative":{"underlying":"Common Stock","underlying_shares":33.898},"source":{"system":"sec-edgar","filing":"0000875320-26-000159","document":"wk-form4_1776456893.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000159/wk-form4_1776456893.xml","form_type":"4"}},{"id":310893,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14445,"kind":"person","name":"Liu Joy","position":1,"cik":"0001847529","reported_name":"Liu Joy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:53:51.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":978,"price":449.17,"value":439288.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":21833,"source":{"system":"sec-edgar","filing":"0000875320-26-000157","document":"wk-form4_1775249628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000157/wk-form4_1775249628.xml","form_type":"4"}},{"id":311134,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:23.000Z","date":"2026-03-27","kind":"sale","planned":true,"acquired":false,"shares":2329,"price":450.95,"value":1050262.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":33076,"source":{"system":"sec-edgar","filing":"0000875320-26-000149","document":"wk-form4_1774987818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000149/wk-form4_1774987818.xml","form_type":"4"}},{"id":311546,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-03-17T20:04:23.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":2329,"price":481.79,"value":1122088.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":35405,"source":{"system":"sec-edgar","filing":"0000875320-26-000140","document":"wk-form4_1773777858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000140/wk-form4_1773777858.xml","form_type":"4"}},{"id":311581,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-13T20:11:50.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":2633,"price":498.42,"value":1312339.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":12489,"source":{"system":"sec-edgar","filing":"0000875320-26-000138","document":"wk-form4_1773432707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000138/wk-form4_1773432707.xml","form_type":"4"}},{"id":311990,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:05:56.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":2437,"price":475.3,"value":1158306.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":15122,"source":{"system":"sec-edgar","filing":"0000875320-26-000136","document":"wk-form4_1772831152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000136/wk-form4_1772831152.xml","form_type":"4"}},{"id":312114,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14445,"kind":"person","name":"Liu Joy","position":1,"cik":"0001847529","reported_name":"Liu Joy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:21:16.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":892,"price":495.96,"value":442396.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Liu's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":22811,"source":{"system":"sec-edgar","filing":"0000875320-26-000134","document":"wk-form4_1772659274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000134/wk-form4_1772659274.xml","form_type":"4"}},{"id":312322,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":1725,"price":496.95,"value":857238.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17)."}],"balance_after":98278,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312321,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":5995,"price":496.16,"value":2974479.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74)."}],"balance_after":100003,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312320,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":15580,"price":495.38,"value":7718020.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78)."}],"balance_after":105998,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312319,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":3498,"price":494.33,"value":1729166.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75)."}],"balance_after":121578,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312318,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2520,"price":493.29,"value":1243090.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77)."}],"balance_after":125076,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312317,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":949,"price":491.3,"value":466243.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85)."}],"balance_after":127596,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312316,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2725,"price":490.54,"value":1336721.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01)."}],"balance_after":128545,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312315,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":460,"price":489.32,"value":225087.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79)."}],"balance_after":131270,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312314,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":3278,"price":488.27,"value":1600549.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56)."}],"balance_after":131730,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312313,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2510,"price":487.13,"value":1222696.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $487.13  (range $486.64 to $487.55)."}],"balance_after":135008,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312312,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":240,"price":482.84,"value":115881.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85)."}],"balance_after":137518,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312311,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":120,"price":481.5,"value":57780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51)."}],"balance_after":137758,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312310,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-03T21:34:23.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":400,"price":479.75,"value":191900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76)."}],"balance_after":137878,"source":{"system":"sec-edgar","filing":"0000875320-26-000129","document":"wk-form4_1772573657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000129/wk-form4_1772573657.xml","form_type":"4"}},{"id":312323,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-03-03T21:25:20.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":2329,"price":480.31,"value":1118641.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025."}],"balance_after":37734,"source":{"system":"sec-edgar","filing":"0000875320-26-000127","document":"wk-form4_1772573117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000127/wk-form4_1772573117.xml","form_type":"4"}},{"id":312418,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T21:10:00.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":357,"price":483.36,"value":172559.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":6624,"source":{"system":"sec-edgar","filing":"0000875320-26-000125","document":"wk-form4_1772485797.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000125/wk-form4_1772485797.xml","form_type":"4"}},{"id":312722,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14560,"kind":"person","name":"WAGNER CHARLES F JR","position":1,"cik":"0001223348","reported_name":"WAGNER CHARLES F JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CO & FO"}}],"security":"Common Stock","published_at":"2026-02-26T23:56:38.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1744,"price":485.11,"value":846031.84,"ownership":{"direct":true},"balance_after":47042,"source":{"system":"sec-edgar","filing":"0000875320-26-000122","document":"wk-form4_1772150196.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000122/wk-form4_1772150196.xml","form_type":"4"}},{"id":312724,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:55:12.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":260,"price":486.35,"value":126451.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":46763,"source":{"system":"sec-edgar","filing":"0000875320-26-000120","document":"wk-form4_1772150109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000120/wk-form4_1772150109.xml","form_type":"4"}},{"id":312723,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:55:12.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1627,"price":485.11,"value":789273.97,"ownership":{"direct":true},"balance_after":47023,"source":{"system":"sec-edgar","filing":"0000875320-26-000120","document":"wk-form4_1772150109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000120/wk-form4_1772150109.xml","form_type":"4"}},{"id":312726,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-26T23:50:47.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":1846,"price":486.35,"value":897802.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."}],"balance_after":55570,"source":{"system":"sec-edgar","filing":"0000875320-26-000118","document":"wk-form4_1772149844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000118/wk-form4_1772149844.xml","form_type":"4"}},{"id":312725,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-26T23:50:47.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1518,"price":485.11,"value":736396.98,"ownership":{"direct":true},"balance_after":57416,"source":{"system":"sec-edgar","filing":"0000875320-26-000118","document":"wk-form4_1772149844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000118/wk-form4_1772149844.xml","form_type":"4"}},{"id":312730,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:48:22.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":2410,"price":489,"value":1178490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":17559,"source":{"system":"sec-edgar","filing":"0000875320-26-000116","document":"wk-form4_1772149699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000116/wk-form4_1772149699.xml","form_type":"4"}},{"id":312729,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:48:22.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":486.35,"value":1215875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."}],"balance_after":19969,"source":{"system":"sec-edgar","filing":"0000875320-26-000116","document":"wk-form4_1772149699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000116/wk-form4_1772149699.xml","form_type":"4"}},{"id":312728,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14435,"kind":"person","name":"McKechnie Duncan","position":1,"cik":"0002062139","reported_name":"McKechnie Duncan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:48:22.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":873,"price":485.11,"value":423501.03,"ownership":{"direct":true},"balance_after":22469,"source":{"system":"sec-edgar","filing":"0000875320-26-000116","document":"wk-form4_1772149699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000116/wk-form4_1772149699.xml","form_type":"4"}},{"id":312719,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-02-26T23:11:08.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":3547,"price":485.11,"value":1720685.17,"ownership":{"direct":true},"balance_after":34797,"source":{"system":"sec-edgar","filing":"0001242825-26-000002","document":"wk-form4_1772147464.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000124282526000002/wk-form4_1772147464.xml","form_type":"4"}},{"id":312727,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14888,"kind":"person","name":"Kewalramani Reshma","position":1,"cik":"0001735944","reported_name":"Kewalramani Reshma","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-26T23:09:50.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":4981,"price":485.11,"value":2416332.91,"ownership":{"direct":true},"balance_after":138278,"source":{"system":"sec-edgar","filing":"0000875320-26-000114","document":"wk-form4_1772147388.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000114/wk-form4_1772147388.xml","form_type":"4"}},{"id":312732,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14631,"kind":"person","name":"Bunnage Mark E.","position":1,"cik":"0002100735","reported_name":"Bunnage Mark E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:06:58.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":620,"price":486.35,"value":301537.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025."}],"balance_after":7284,"source":{"system":"sec-edgar","filing":"0000875320-26-000112","document":"wk-form4_1772147216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000112/wk-form4_1772147216.xml","form_type":"4"}},{"id":312731,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14631,"kind":"person","name":"Bunnage Mark E.","position":1,"cik":"0002100735","reported_name":"Bunnage Mark E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:06:58.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":582,"price":485.11,"value":282334.02,"ownership":{"direct":true},"balance_after":7904,"source":{"system":"sec-edgar","filing":"0000875320-26-000112","document":"wk-form4_1772147216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000112/wk-form4_1772147216.xml","form_type":"4"}},{"id":312733,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14509,"kind":"person","name":"Bozic Carmen","position":1,"cik":"0001790029","reported_name":"Bozic Carmen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and CMO"}}],"security":"Common Stock","published_at":"2026-02-26T23:05:21.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1453,"price":485.11,"value":704864.83,"ownership":{"direct":true},"balance_after":40063,"source":{"system":"sec-edgar","filing":"0000875320-26-000110","document":"wk-form4_1772147118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000110/wk-form4_1772147118.xml","form_type":"4"}},{"id":312737,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:01:56.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":945,"price":486.35,"value":459600.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025."}],"balance_after":13659,"source":{"system":"sec-edgar","filing":"0000875320-26-000108","document":"wk-form4_1772146913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000108/wk-form4_1772146913.xml","form_type":"4"}},{"id":312736,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14917,"kind":"person","name":"Biller Jonathan","position":1,"cik":"0001744749","reported_name":"Biller Jonathan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-26T23:01:56.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1144,"price":485.11,"value":554965.84,"ownership":{"direct":true},"balance_after":14604,"source":{"system":"sec-edgar","filing":"0000875320-26-000108","document":"wk-form4_1772146913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000108/wk-form4_1772146913.xml","form_type":"4"}},{"id":312735,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:00:11.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":668,"price":486.35,"value":324881.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025."}],"balance_after":18432,"source":{"system":"sec-edgar","filing":"0000875320-26-000106","document":"wk-form4_1772146808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000106/wk-form4_1772146808.xml","form_type":"4"}},{"id":312734,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14916,"kind":"person","name":"Atkinson Edward Morrow III","position":1,"cik":"0001914164","reported_name":"Atkinson Edward Morrow III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Ops. Off."}}],"security":"Common Stock","published_at":"2026-02-26T23:00:11.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":1627,"price":485.11,"value":789273.97,"ownership":{"direct":true},"balance_after":19100,"source":{"system":"sec-edgar","filing":"0000875320-26-000106","document":"wk-form4_1772146808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000106/wk-form4_1772146808.xml","form_type":"4"}},{"id":312739,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-26T22:56:21.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":223,"price":486.35,"value":108456.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025."}],"balance_after":6981,"source":{"system":"sec-edgar","filing":"0000875320-26-000104","document":"wk-form4_1772146579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000104/wk-form4_1772146579.xml","form_type":"4"}},{"id":312738,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14190,"kind":"person","name":"Ambrose Kristen","position":1,"cik":"0001856587","reported_name":"Ambrose Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-26T22:56:21.000Z","date":"2026-02-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":546,"price":485.11,"value":264870.06,"ownership":{"direct":true},"balance_after":7204,"source":{"system":"sec-edgar","filing":"0000875320-26-000104","document":"wk-form4_1772146579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000104/wk-form4_1772146579.xml","form_type":"4"}},{"id":312985,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":25026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":187.53,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":25026},"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312984,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":23479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":155.57,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":23479},"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312983,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":4237,"price":471.43,"value":1997448.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $471.43 (range $471.10 to $472.03)."}],"balance_after":58934,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312982,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":11712,"price":470.54,"value":5510964.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $470.54 (range $470.10 to $471.08)."}],"balance_after":63171,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312981,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":7241,"price":469.61,"value":3400446.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $469.61 (range $469.10 to $470.05)."}],"balance_after":74883,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312980,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":19662,"price":468.57,"value":9213023.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $468.57 (range $468.10 to $469.09)."}],"balance_after":82124,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312979,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":10263,"price":467.75,"value":4800518.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $467.75 (range $467.09 to $468.05)."}],"balance_after":101786,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312978,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":1848,"price":465.8,"value":860798.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $465.80 (range $465.54 to $466.49)."}],"balance_after":112049,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312977,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":2730,"price":465.05,"value":1269586.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $465.05 (range $464.48 to $465.46)."}],"balance_after":113897,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312976,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":920,"price":463.91,"value":426797.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 11/18/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $463.91 (range $463.44 to $464.28)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":116627,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312975,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":25026,"price":187.53,"value":4693125.78,"ownership":{"direct":true},"balance_after":117547,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":312974,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14405,"kind":"person","name":"Sachdev Amit","position":1,"cik":"0001406338","reported_name":"Sachdev Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Chief Patient & Ext Af Off"}}],"security":"Common Stock","published_at":"2026-02-23T21:21:44.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":23479,"price":155.57,"value":3652628.03,"ownership":{"direct":true},"balance_after":92521,"source":{"system":"sec-edgar","filing":"0000875320-26-000102","document":"wk-form4_1771881700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000102/wk-form4_1771881700.xml","form_type":"4"}},{"id":313127,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14560,"kind":"person","name":"WAGNER CHARLES F JR","position":1,"cik":"0001223348","reported_name":"WAGNER CHARLES F JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CO & FO"}}],"security":"Common Stock","published_at":"2026-02-19T21:30:13.000Z","date":"2026-02-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":2294,"price":483.75,"value":1109722.5,"ownership":{"direct":true},"balance_after":48786,"source":{"system":"sec-edgar","filing":"0000875320-26-000100","document":"wk-form4_1771536607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000100/wk-form4_1771536607.xml","form_type":"4"}},{"id":313126,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14560,"kind":"person","name":"WAGNER CHARLES F JR","position":1,"cik":"0001223348","reported_name":"WAGNER CHARLES F JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CO & FO"}}],"security":"Common Stock","published_at":"2026-02-19T21:30:13.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":7365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that vests in installments beginning on February 20, 2027."}],"balance_after":51080,"source":{"system":"sec-edgar","filing":"0000875320-26-000100","document":"wk-form4_1771536607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000100/wk-form4_1771536607.xml","form_type":"4"}},{"id":313131,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":368,"price":473.68,"value":174314.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":48650,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}},{"id":313130,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14404,"kind":"person","name":"Tatsis Ourania","position":1,"cik":"0001789815","reported_name":"Tatsis Ourania","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. & Quality Off."}}],"security":"Common Stock","published_at":"2026-02-19T21:28:26.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":609,"price":489.46,"value":298081.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."}],"balance_after":49018,"source":{"system":"sec-edgar","filing":"0000875320-26-000098","document":"wk-form4_1771536504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789815/000087532026000098/wk-form4_1771536504.xml","form_type":"4"}}],"next_cursor":"2026-02-19T21:28:26.000000Z,313130"}